Heidelberg Pharma AG

Equities

HPHA

DE000A11QVV0

Biotechnology & Medical Research

Market Closed - Xetra Other stock markets 16:36:05 29/04/2024 BST			5-day change	1st Jan Change
3 ^EUR	+1.01%		0.00%	-19.79%

04-25	Heidelberg Pharma AG Reports Earnings Results for the First Quarter Ended February 29, 2024	CI
04-23	Transcript : Heidelberg Pharma AG - Special Call

Huadong Medicine Co., Ltd agreed to acquire 9% stake in Heidelberg Pharma AG from dievini Hopp BioTech holding GmbH & Co. KG.

February 26, 2022

Huadong Medicine Co., Ltd (SZSE:000963) agreed to acquire 9% stake in Heidelberg Pharma AG (XTRA:HPHA) from dievini Hopp BioTech holding GmbH & Co. KG on February 27, 2022. Sabrina Kulenkamp, Rick van Aerssen, Uwe Salaschek, Jan Brinkmann, Counsel Tanja Walter-Yadegardjam, Alan Wang and Ya Ma of Freshfields Bruckhaus Deringer LLP acted as legal advisor to Huadong Medicine Co., Ltd. Bernt Paudtke, Christian Bürger, Lutz Pospiech and Tobias Reichenberger of GÖRG Rechtsanwälte acted as legal advisor to Heidelberg Pharma AG.

Christina Eschenfelder of RITTERSHAUS Rechtsanwälte Partnerschaftsgesellschaft mbB acted as legal advisor to dievini Hopp BioTech holding GmbH & Co. KG. Lazard acted as financial advisor to Huadong Medicine.

Latest news about Heidelberg Pharma AG

Heidelberg Pharma AG Reports Earnings Results for the First Quarter Ended February 29, 2024	04-25	CI
Transcript : Heidelberg Pharma AG - Special Call	04-23
Heidelberg Pharma Wins US FDA Orphan Drug Designation for Multiple Myeloma Treatment	03-27	MT
Transcript : Heidelberg Pharma AG, 2023 Earnings Call, Mar 25, 2024	03-25
Heidelberg Pharma AG Reports Earnings Results for the Full Year Ended November 30, 2023	03-25	CI
Heidelberg Pharma Concludes Royalty Purchase Deal with HealthCare Royalty	03-19	MT
Heidelberg Pharma CEO to Retire; Chief Scientific Officer Named Successor	11-29	MT
Heidelberg Pharma Unit Secures European Patent for Amanitin Toxin-Based Antibody-Drug Conjugates	11-15	MT
Heidelberg Pharma AG Reports Earnings Results for the Nine Months Ended August 31, 2023	12/10/23	CI
Heidelberg Pharma Provides Update on Phase I/IIa Clinical Trial with Lead Candidate HDP-101	19/09/23	CI
Heidelberg Pharma Gets Milestone Payment for Antibody Technology	08/08/23	MT
Transcript : Heidelberg Pharma AG, H1 2023 Earnings Call, Jul 13, 2023	13/07/23
Heidelberg Pharma AG Reports Earnings Results for the Second Quarter and Six Months Ended May 31, 2023	13/07/23	CI
Heidelberg Pharma Ag Announces Executive Changes	08/05/23	CI
Germany's Heidelberg Pharma Appoints CFO	05/05/23	MT
Heidelberg Pharma AG Reports Earnings Results for the First Quarter Ended February 28, 2023	13/04/23	CI
Heidelberg Pharma AG Provides Earnings Guidance for the Year 2023	27/03/23	CI
Transcript : Heidelberg Pharma AG, 2022 Earnings Call, Mar 27, 2023	27/03/23
Heidelberg Pharma AG Reports Earnings Results for the Full Year Ended November 30, 2022	24/03/23	CI
Heidelberg Pharma AG Reports Earnings Results for the Full Year Ended November 30, 2022	24/03/23	CI
Heidelberg Pharma AG Auditor Raises 'Going Concern' Doubt	23/03/23	CI
Transcript : Heidelberg Pharma AG - Special Call	15/02/23
Heidelberg Pharma Signs Research and Exclusive Option Agreement with Binghamton University on Immunostimulatory Technology Platform	16/12/22	CI
Heidelberg Pharma Ag Announces Encouraging Clinical Data from Two Antibody Drug Conjugates Based on Heidelberg Pharma’s ATAC Technology	13/12/22	CI
Heidelberg Pharma AG Reports Earnings Results for the Nine Months Ended August 31, 2022	13/10/22	CI

Chart Heidelberg Pharma AG

Duration

Period

More charts

Company Profile

Heidelberg Pharma AG, formerly Wilex AG, is a Germany-based Company, which is engaged in the biopharmaceuticals sector. The Company focuses on the research and development of therapy treatments for oncology area. It aims at applying toxin Amanitin into cancer therapies using its Antibody Targeted Amanitin Conjugate (ATAC) technology. The Companyâs pipeline includes a number of drug candidates, such as HDP-101, a B-cell maturation antigen ATAC for multiple myeloma; PSMA-ATAC, prostate-specific membrane antigens, and CD19-ATAC, a B-lymphocyte antigen. Through partnerships, the Company develops clinical assets, including MESUPRON, REDECTANE and RENCAREX. It also offers preclinical contract research services.

Sector

Biotechnology & Medical Research

Calendar

12/05/2024 - PEGS Boston Conference

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3 EUR

Average target price

11.3 EUR

Spread / Average Target

+276.67%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
HEIDELBERG PHARMA AG	-19.79%	148M
VERTEX PHARMACEUTICALS INCORPORATED	-2.63%	103B
REGENERON PHARMACEUTICALS, INC.	+1.62%	95.28B
ARGENX SE	+1.46%	22.15B
BIONTECH SE	-16.67%	21.02B
GENMAB A/S	-8.58%	18.15B
WUXI APPTEC CO., LTD.	-38.74%	16.73B
BEIGENE, LTD.	-13.21%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+5.41%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.57%	12.17B

Bio Therapeutic Drugs